دورية أكاديمية
أعرض في EDS

Partially Hydrolysed Whey Has Superior Allergy Preventive Capacity Compared to Intact Whey Regardless of Amoxicillin Administration in Brown Norway Rats.

التفاصيل البيبلوغرافية
العنوان: Partially Hydrolysed Whey Has Superior Allergy Preventive Capacity Compared to Intact Whey Regardless of Amoxicillin Administration in Brown Norway Rats.
المؤلفون: Graversen KB; National Food Institute, Technical University of Denmark, Kgs. Lyngby, Denmark., Larsen JM; National Food Institute, Technical University of Denmark, Kgs. Lyngby, Denmark., Pedersen SS; National Food Institute, Technical University of Denmark, Kgs. Lyngby, Denmark., Sørensen LV; Research & Development, Arla Foods Ingredients Group P/S, Videbæk, Denmark., Christoffersen HF; Research & Development, Arla Foods Ingredients Group P/S, Videbæk, Denmark., Jacobsen LN; Strategic Business Unit Pediatric, Arla Foods Ingredients Group P/S, Viby J, Denmark., Halken S; Hans Christian Andersen Children's Hospital, Odense University Hospital, Odense, Denmark., Licht TR; National Food Institute, Technical University of Denmark, Kgs. Lyngby, Denmark., Bahl MI; National Food Institute, Technical University of Denmark, Kgs. Lyngby, Denmark., Bøgh KL; National Food Institute, Technical University of Denmark, Kgs. Lyngby, Denmark.
المصدر: Frontiers in immunology [Front Immunol] 2021 Aug 31; Vol. 12, pp. 705543. Date of Electronic Publication: 2021 Aug 31 (Print Publication: 2021).
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Lausanne : Frontiers Research Foundation]
مواضيع طبية MeSH: Gastrointestinal Microbiome*/drug effects , Gastrointestinal Microbiome*/immunology , Milk Hypersensitivity*/immunology , Milk Hypersensitivity*/prevention & control, Amoxicillin/*pharmacology , Protein Hydrolysates/*pharmacology , Whey Proteins/*pharmacology, Animals ; Humans ; Rats
مستخلص: Background: It remains largely unknown how physicochemical properties of hydrolysed infant formulas influence their allergy preventive capacity, and results from clinical and animal studies comparing the preventive capacity of hydrolysed infant formula with conventional infant formula are inconclusive. Thus, the use of hydrolysed infant formula for allergy prevention in atopy-prone infants is highly debated. Furthermore, knowledge on how gut microbiota influences allergy prevention remains scarce.
Objective: To gain knowledge on (1) how physicochemical properties of hydrolysed whey products influence the allergy preventive capacity, (2) whether host microbiota disturbance influences allergy prevention, and (3) to what extent hydrolysed whey products influence gut microbiota composition.
Methods: The preventive capacity of four different ad libitum administered whey products was investigated in Brown Norway rats with either a conventional or an amoxicillin-disturbed gut microbiota. The preventive capacity of products was evaluated as the capacity to reduce whey-specific sensitisation and allergic reactions to intact whey after intraperitoneal post-immunisations with intact whey. Additionally, the direct effect of the whey products on the growth of gut bacteria derived from healthy human infant donors was evaluated by in vitro incubation.
Results: Two partially hydrolysed whey products with different physicochemical characteristics were found to be superior in preventing whey-specific sensitisation compared to intact and extensively hydrolysed whey products. Daily oral amoxicillin administration, initiated one week prior to intervention with whey products, disturbed the gut microbiota but did not impair the prevention of whey-specific sensitisation. The in vitro incubation of infant faecal samples with whey products indicated that partially hydrolysed whey products might confer a selective advantage to enterococci.
Conclusions: Our results support the use of partially hydrolysed whey products for prevention of cow's milk allergy in atopy-predisposed infants regardless of their microbiota status. However, possible direct effects of partially hydrolysed whey products on gut microbiota composition warrants further investigation.
Competing Interests: LJ, HC, and LS are employees at Arla Foods Ingredients. KB has ongoing collaboration with the company Arla Foods Ingredients, which supplied the whey protein products for the current study. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2021 Graversen, Larsen, Pedersen, Sørensen, Christoffersen, Jacobsen, Halken, Licht, Bahl and Bøgh.)
References: Proc Natl Acad Sci U S A. 2014 Sep 9;111(36):13145-50. (PMID: 25157157)
Nat Med. 2019 Mar;25(3):448-453. (PMID: 30643289)
Nat Methods. 2016 Jul;13(7):581-3. (PMID: 27214047)
Nat Med. 2016 May;22(5):524-30. (PMID: 27064448)
Clin Exp Allergy. 2020 Jun;50(6):708-721. (PMID: 32077177)
Pediatrics. 2008 Jan;121(1):183-91. (PMID: 18166574)
Food Sci Nutr. 2015 Jan;3(1):81-90. (PMID: 25648153)
Cochrane Database Syst Rev. 2018 Oct 19;10:CD003664. (PMID: 30338526)
Clin Exp Allergy. 2013 Feb;43(2):198-211. (PMID: 23331561)
Science. 2015 Aug 28;349(6251):989-93. (PMID: 26160380)
FEMS Microbiol Lett. 2012 Dec;337(1):38-47. (PMID: 22967145)
Nat Microbiol. 2018 Nov;3(11):1255-1265. (PMID: 30349083)
Nat Med. 2019 Jul;25(7):1164-1174. (PMID: 31235962)
BMJ. 2016 Mar 08;352:i974. (PMID: 26956579)
Allergy. 2014 May;69(5):590-601. (PMID: 24697491)
Appl Environ Microbiol. 2011 Dec;77(23):8336-44. (PMID: 21984234)
JAMA Pediatr. 2018 Jun 4;172(6):e180315. (PMID: 29610864)
J Allergy Clin Immunol. 2010 Dec;126(6):1119-28.e12. (PMID: 21134569)
Sci Rep. 2018 Jul 25;8(1):11192. (PMID: 30046129)
PLoS One. 2010 Mar 24;5(3):e9836. (PMID: 20352091)
Epidemiology. 2013 Mar;24(2):303-9. (PMID: 23348066)
Clin Vaccine Immunol. 2007 Feb;14(2):190-7. (PMID: 17151185)
Int Arch Allergy Immunol. 2019;178(4):307-314. (PMID: 30759437)
Appl Environ Microbiol. 2007 Aug;73(16):5261-7. (PMID: 17586664)
Allergy. 2014 Aug;69(8):992-1007. (PMID: 24816523)
Gut Microbes. 2017 Jan 2;8(1):17-32. (PMID: 27973989)
Pediatr Allergy Immunol. 2016 May;27(3):254-62. (PMID: 26663491)
FEMS Microbiol Ecol. 2020 May 1;96(5):. (PMID: 32275305)
J Allergy Clin Immunol. 2018 Jan;141(1):41-58. (PMID: 29157945)
Int Arch Allergy Immunol. 2013;161(1):21-36. (PMID: 23257607)
Clin Exp Allergy. 2009 Oct;39(10):1611-21. (PMID: 19689460)
Med J Aust. 2019 Feb;210(2):89-93. (PMID: 30636277)
J Antimicrob Chemother. 2018 Feb 1;73(suppl_2):ii2-ii10. (PMID: 29490062)
Toxicol Lett. 2011 Mar 25;201(3):264-9. (PMID: 21251954)
Microb Ecol Health Dis. 2015 May 29;26:27663. (PMID: 26028277)
Clin Rev Allergy Immunol. 2018 Oct;55(2):107-117. (PMID: 29488131)
Allergy. 2020 Jun;75(6):1446-1449. (PMID: 31705686)
Clin Exp Allergy. 2017 Feb;47(2):236-244. (PMID: 27562571)
Allergy Asthma Clin Immunol. 2018 Nov 1;14:42. (PMID: 30410548)
Allergy. 2015 Aug;70(8):963-72. (PMID: 25864712)
J Allergy Clin Immunol. 2011 Aug;128(2):360-365.e4. (PMID: 21696814)
Front Immunol. 2019 Aug 02;10:1819. (PMID: 31428100)
Arch Dis Child. 1997 Jul;77(1):4-10. (PMID: 9279143)
Pediatr Allergy Immunol. 2011 Dec;22(8):820-6. (PMID: 21933283)
Pediatr Allergy Immunol. 2018 Jun;29(4):433-440. (PMID: 29518286)
Clin Exp Allergy. 1998 Mar;28(3):368-75. (PMID: 9543088)
Int Arch Allergy Immunol. 2001 Aug;125(4):316-21. (PMID: 11574753)
Sci Transl Med. 2016 Jun 15;8(343):343ra81. (PMID: 27306663)
ISME J. 2007 May;1(1):56-66. (PMID: 18043614)
Clin Exp Allergy. 2004 Apr;34(4):663-70. (PMID: 15080823)
J Allergy Clin Immunol. 2007 Sep;120(3):638-46. (PMID: 17628647)
Front Microbiol. 2020 Mar 26;11:496. (PMID: 32292395)
ISME J. 2016 Mar;10(3):707-20. (PMID: 26359913)
J Immunol. 2010 Apr 1;184(7):3433-41. (PMID: 20181882)
Int J Food Microbiol. 2006 Jan 15;106(1):1-24. (PMID: 16216368)
BMC Microbiol. 2020 Nov 9;20(1):337. (PMID: 33167908)
Pediatrics. 2019 Apr;143(4):. (PMID: 30886111)
Science. 2015 Aug 28;349(6251):993-7. (PMID: 26272906)
Pediatr Allergy Immunol. 2019 May;30(3):370-377. (PMID: 30672606)
Nat Biotechnol. 2019 Aug;37(8):852-857. (PMID: 31341288)
J Immunol. 2004 Jun 1;172(11):6978-87. (PMID: 15153518)
Front Immunol. 2012 Jul 18;3:203. (PMID: 22826710)
Ann Allergy. 1992 May;68(5):419-24. (PMID: 1586005)
فهرسة مساهمة: Keywords: IgA; allergy prevention; cow’s milk allergy; food allergy; hypoallergenic infant formula; iTreg; microbiota; β-lactam antibiotic
المشرفين على المادة: 0 (Protein Hydrolysates)
0 (Whey Proteins)
804826J2HU (Amoxicillin)
تواريخ الأحداث: Date Created: 20210917 Date Completed: 20211220 Latest Revision: 20211220
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC8438296
DOI: 10.3389/fimmu.2021.705543
PMID: 34531857
قاعدة البيانات: MEDLINE
الوصف
تدمد:1664-3224
DOI:10.3389/fimmu.2021.705543